Margaret G. Mcglynn - 08 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
08 Apr 2022
Net transactions value
-$763,380
Form type
4
Filing time
12 Apr 2022, 16:05:43 UTC
Previous filing
04 Apr 2022
Next filing
03 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $637,700 +5,000 +455% $127.54 6,099 08 Apr 2022 Direct
transaction VRTX Common Stock Sale $1,372,931 -4,900 -80% $280.19 1,199 08 Apr 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $28,149 -100 -8.3% $281.49 1,099 08 Apr 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -5,000 -50% $0.000000 5,000 08 Apr 2022 Common Stock 5,000 $127.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
F2 Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $280.19 (range $280.00 to $280.95).
F4 Fully vested.